View Post

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival (PFS) and a trend toward improved overall survival (OS) in patients with BRCA-like triple-negative breast cancer (TNBC), according to data from the phase 2 SWOG S1416 trial (NCT02595905) presented at the 2020 ASCO Virtual Scientific Program.1 In the trial, 248 patients …